Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | EO2401 |
Synonyms | |
Therapy Description |
EO2401 is a cancer vaccine comprising microbiome-derived peptides that are similar to IL13Ralpha2, BIRC5, and FOXM1, potentially resulting in enhanced anti-tumor immune response (J Clin Oncol 40, no. 16_suppl (June 01, 2022) 2034-2034). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
EO2401 | EO 2401|EO-2401 | EO2401 is a cancer vaccine comprising microbiome-derived peptides that are similar to IL13Ralpha2, BIRC5, and FOXM1, potentially resulting in enhanced anti-tumor immune response (J Clin Oncol 40, no. 16_suppl (June 01, 2022) 2034-2034). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04116658 | Phase Ib/II | EO2401 | First-in-Human, Phase 1b/2a Trial of a Multipeptide Therapeutic Vaccine in Patients With Progressive Glioblastoma (ROSALIE) | Completed | USA | FRA | ESP | DEU | 0 |